Skip to main content
Top
Published in: BMC Gastroenterology 1/2012

Open Access 01-12-2012 | Research article

Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care

Authors: Eugena Stamuli, Karen Bloor, Hugh MacPherson, Helen Tilbrook, Tracy Stuardi, Sally Brabyn, David Torgerson

Published in: BMC Gastroenterology | Issue 1/2012

Login to get access

Abstract

Background

There is insufficient evidence to determine whether acupuncture is a cost-effective treatment for irritable bowel syndrome. The objective of this study is to assess the cost-effectiveness of acupuncture as an adjunct to usual care versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS).

Methods

Cost-utility analysis conducted alongside a pragmatic, multicentre, randomised controlled trial. 233 patients with irritable bowel syndrome were randomly allocated to either acupuncture plus usual care, or usual care alone. Cost-effectiveness outcomes are expressed in terms of incremental cost per quality adjusted life year (QALY) at one year after randomisation. Costs were estimated from the UK National Health Service perspective for a time horizon of one year. Cost-utility ratios were estimated based on complete case analysis for the base case analysis, where only patients with available EQ-5D and cost data were included. Sensitivity analyses comprised a multiple imputation approach for missing data and a subgroup analysis for the more severe cases of IBS.

Results

The base case analysis showed acupuncture to be marginally more effective than usual care (gain of 0.0035 QALYs, 95% CI: -0.00395 to 0.0465) and more expensive (incremental cost of £218 per patient (95% CI: 55.87 to 492.87) resulting in an incremental cost-effectiveness ratio of approximately £62,500. Sensitivity analysis using multiple imputation for missing data resulted in acupuncture appearing less effective and more costly than usual care, so usual care is dominant. Subgroup analysis selecting the most severe cases of IBS (Symptom Severity Score of over 300) suggested that acupuncture may be a cost-effective treatment option for this group, with a cost-per-QALY of £6,500.

Conclusions

Acupuncture as an adjunct to usual care is not a cost-effective option for the whole IBS population; however it may be cost-effective for those with more severe irritable bowel syndrome.

Trial registration

Current Controlled Trials ISRCTN08827905
Appendix
Available only for authorised users
Literature
1.
go back to reference Rey E, Talley NJ: Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Digestive and Liver Disease. 2009, 41: 772-780.CrossRefPubMed Rey E, Talley NJ: Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Digestive and Liver Disease. 2009, 41: 772-780.CrossRefPubMed
2.
go back to reference Lea R, Whorwell PJ: Quality of life in irritable bowel syndrome. Pharmacoeconomics. 2001, 19: 643-653.CrossRefPubMed Lea R, Whorwell PJ: Quality of life in irritable bowel syndrome. Pharmacoeconomics. 2001, 19: 643-653.CrossRefPubMed
3.
go back to reference Akehurst RL, Brazier JE, Mathers N, O’Keefe C, Kaltenthaler E, et al: Health-related quality of life and cost impact of irritable bowel syndrom in a UK primary care setting. Pharmacoeconomics. 2002, 20: 455-462.CrossRefPubMed Akehurst RL, Brazier JE, Mathers N, O’Keefe C, Kaltenthaler E, et al: Health-related quality of life and cost impact of irritable bowel syndrom in a UK primary care setting. Pharmacoeconomics. 2002, 20: 455-462.CrossRefPubMed
4.
go back to reference Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E: Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther. 1997, 11: Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E: Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther. 1997, 11:
5.
go back to reference Wells NEJ, Hahn BA, Whorwell PJ: Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther. 1997, 11: 10119-11030.CrossRef Wells NEJ, Hahn BA, Whorwell PJ: Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther. 1997, 11: 10119-11030.CrossRef
6.
go back to reference Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, et al: Health-Related Quality of Life and Health Care Costs in Severe, Refractory Irritable Bowel Syndrome. Ann Intern Med. 2001, 134: 860-868.CrossRefPubMed Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, et al: Health-Related Quality of Life and Health Care Costs in Severe, Refractory Irritable Bowel Syndrome. Ann Intern Med. 2001, 134: 860-868.CrossRefPubMed
7.
go back to reference Hahn B, Yan S, Strassels S: Impact of irritable bowel syndrome on quality of life and resource us in the United States and United Kingdom. Digestion. 1999, 60: 77-81.CrossRefPubMed Hahn B, Yan S, Strassels S: Impact of irritable bowel syndrome on quality of life and resource us in the United States and United Kingdom. Digestion. 1999, 60: 77-81.CrossRefPubMed
9.
go back to reference Drossman DA, Whitehead WE, Camilleri M: Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997, 112: 2120-2137.CrossRefPubMed Drossman DA, Whitehead WE, Camilleri M: Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997, 112: 2120-2137.CrossRefPubMed
10.
go back to reference Lim B, Manheimer E, Lao L, Ziea E, Wisniewski J, Liu J, et al: Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2006, 4: CD005111-PubMed Lim B, Manheimer E, Lao L, Ziea E, Wisniewski J, Liu J, et al: Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2006, 4: CD005111-PubMed
11.
go back to reference MacPherson H, Bland M, Bloor K, Cox H, Geddes D, Kang’ombe A, Reynolds J, Stamuli E, Stuardi T, Tilbrook H, et al: Acupuncture for irritable bowel syndrome: a protocol for a pragmatic randomised controlled trial. BMC Gastroenterol. 2010, 10: 63-CrossRefPubMedPubMedCentral MacPherson H, Bland M, Bloor K, Cox H, Geddes D, Kang’ombe A, Reynolds J, Stamuli E, Stuardi T, Tilbrook H, et al: Acupuncture for irritable bowel syndrome: a protocol for a pragmatic randomised controlled trial. BMC Gastroenterol. 2010, 10: 63-CrossRefPubMedPubMedCentral
12.
go back to reference MacPherson H, Tilbrook H, Bland JM, Bloor K, Brabyn S, Cox H, Kang’ombe AR, Man MS, Stuardi T, Torgerson D, Watt I, Whorwell P: Acupuncture for irritable bowel syndrome: primary care based pragmatic randomised controlled trial. BMC Gastroenterology. 2012, 12: 139-CrossRef MacPherson H, Tilbrook H, Bland JM, Bloor K, Brabyn S, Cox H, Kang’ombe AR, Man MS, Stuardi T, Torgerson D, Watt I, Whorwell P: Acupuncture for irritable bowel syndrome: primary care based pragmatic randomised controlled trial. BMC Gastroenterology. 2012, 12: 139-CrossRef
13.
go back to reference MacPherson H, et al: Acupuncture for irritable bowel syndrome: primary care based pragmatic randomised controlled trial. BMC Gastroenterology. 2012, 12: 150-CrossRefPubMedPubMedCentral MacPherson H, et al: Acupuncture for irritable bowel syndrome: primary care based pragmatic randomised controlled trial. BMC Gastroenterology. 2012, 12: 150-CrossRefPubMedPubMedCentral
15.
go back to reference Kind P: EuroQol instrument: an index of health-related quality of life. Quality of life and pharmacoeconomics in clinical trials. Edited by: Spilker B. 1996, Philadelphia: Lippincott-Raven Kind P: EuroQol instrument: an index of health-related quality of life. Quality of life and pharmacoeconomics in clinical trials. Edited by: Spilker B. 1996, Philadelphia: Lippincott-Raven
16.
go back to reference Dolan P, Gudex C, Kind P, Williams A: Discussion Paper No 138, Centre for Health Economics. A social tarif for EuroQol: Results from a UK general population survey. 1995, University of York: York Dolan P, Gudex C, Kind P, Williams A: Discussion Paper No 138, Centre for Health Economics. A social tarif for EuroQol: Results from a UK general population survey. 1995, University of York: York
20.
go back to reference Manca A, Hawkins N, Sculpher MJ: Estimating mean QALYs in trial-based cost-effectivenessanalysis: the importance of controlling for baseline utility. Health Econ. 2005, 14: 487-496.CrossRefPubMed Manca A, Hawkins N, Sculpher MJ: Estimating mean QALYs in trial-based cost-effectivenessanalysis: the importance of controlling for baseline utility. Health Econ. 2005, 14: 487-496.CrossRefPubMed
21.
go back to reference Francis CY, Morris J, Whorwell PJ: The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997, 11: 395-402.CrossRefPubMed Francis CY, Morris J, Whorwell PJ: The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997, 11: 395-402.CrossRefPubMed
22.
go back to reference Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000, 119: 654-660.CrossRefPubMed Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000, 119: 654-660.CrossRefPubMed
23.
go back to reference Miller V, Hopkins L, Whorwell PJ: Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004, 2: 1064-1068.CrossRefPubMed Miller V, Hopkins L, Whorwell PJ: Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004, 2: 1064-1068.CrossRefPubMed
Metadata
Title
Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care
Authors
Eugena Stamuli
Karen Bloor
Hugh MacPherson
Helen Tilbrook
Tracy Stuardi
Sally Brabyn
David Torgerson
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2012
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-12-149

Other articles of this Issue 1/2012

BMC Gastroenterology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine